Competencies required for this project are all presents within the Pharm’image biocluster, progressively developed by the consortium members and the available technical platforms (cyclotron, radiochemistry laboratory, preclinical and clinical PET imaging). This project has been the driver in the building of Pharm’image.
This project has been the driver in the building of Pharm’image.
The clinical development of the first Nanocyclix® PET radiotracer targeting the EGFR protein has been initiated in July 2016. CGFL is the promoter of the phase 0/I clinical trial.
Commercialization of at least 2 novel radiotracers is expected for this project with clinical use in the treatment follow-up of patients with cancer.
This project has been initiated in 2009 with the support of BPI-France (10.5 M€ over a total budget of 25 M€).
Oncodesign is the leader of the project consortium including Ariana Pharmaceuticals and Cyclopharma.
http://www.pharmimage.fr/en/publications-of-imakinib-program/
